Cargando…

Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole

OBJECTIVE: Digital medicine system (DMS) is a novel drug–device combination that objectively measures and reports medication ingestion. The DMS consists of medication embedded with an ingestible sensor (digital medicine), a wearable sensor, and software applications. This study evaluated usability o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peters-Strickland, Timothy, Pestreich, Linda, Hatch, Ainslie, Rohatagi, Shashank, Baker, Ross A, Docherty, John P, Markovtsova, Lada, Raja, Praveen, Weiden, Peter J, Walling, David P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067053/ https://www.ncbi.nlm.nih.gov/pubmed/27785036 http://dx.doi.org/10.2147/NDT.S116029

Ejemplares similares

Participant Engagement and Symptom Improvement: Aripiprazole Tablets with Sensor for the Treatment of Schizophrenia
por: Cochran, Jeffrey M, et al.
Publicado: (2022)

Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2018)

Visible Spectrophotometric Method for the Determination of Aripiprazole in Tablets
por: Jain, R., et al.
Publicado: (2011)

Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study
por: Nasrallah, Henry A., et al.
Publicado: (2021)

Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia
por: McEvoy, Joseph P., et al.
Publicado: (2021)

Aripiprazole for late-life schizophrenia
por: Rado, Jeffrey, et al.
Publicado: (2010)

Review of depot aripiprazole for schizophrenia
por: Motiwala, Farha Bilal, et al.
Publicado: (2013)

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb, Nilufar, et al.
Publicado: (2012)

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia
por: Kane, John M., et al.
Publicado: (2013)

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
por: Citrome, Leslie, et al.
Publicado: (2019)

Development and application of an aggregate adherence metric derived from population pharmacokinetics to inform clinical trial enrichment
por: Knights, Jonathan, et al.
Publicado: (2015)

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal(®) Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
por: Hard, Marjie L., et al.
Publicado: (2019)

Aripiprazole: the evidence of its therapeutic impact in schizophrenia
por: Winlow, William, et al.
Publicado: (2006)

Effect of Aripiprazole on Mismatch Negativity (MMN) in Schizophrenia
por: Zhou, Zhenhe, et al.
Publicado: (2013)

Aripiprazole-associated tic in a schizophrenia patient
por: Guo, Xieli, et al.
Publicado: (2015)

Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study
por: Weiden, Peter J., et al.
Publicado: (2020)

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study
por: Peters-Strickland, Timothy, et al.
Publicado: (2015)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
por: Hattori, Saki, et al.
Publicado: (2023)

Efficacy and tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Andrade, Chittaranjan
Publicado: (2004)

Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Chavda, R.K., et al.
Publicado: (2004)

Retrospective Study of Japanese Patients with Schizophrenia Treated with Aripiprazole
por: Tanioka, Tetsuya, et al.
Publicado: (2012)

Treatment of refractory catatonic schizophrenia with low dose aripiprazole
por: Sasaki, Tsuyoshi, et al.
Publicado: (2012)

Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
por: Tien, Yun, et al.
Publicado: (2022)

Cost-Effectiveness of Aripiprazole Tablets with Sensor versus Oral Atypical Antipsychotics for the Treatment of Schizophrenia Using a Patient-Level Microsimulation Modeling Approach
por: Chopra, Avijeet S, et al.
Publicado: (2023)

Human factors evaluation of a novel digital medicine system in psychiatry
por: Peters-Strickland, Timothy, et al.
Publicado: (2018)

Expert Consensus Survey on Digital Health Tools for Patients With Serious Mental Illness: Optimizing for User Characteristics and User Support
por: Hatch, Ainslie, et al.
Publicado: (2018)

Severe arrhythmia induced by orally disintegrating aripiprazole tablets (Bosiqing(®)): a case report
por: Shao, Qing, et al.
Publicado: (2015)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
por: James, Suneeta, et al.
Publicado: (2016)

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

A Case of Hypersexuality in a Patient Receiving Aripiprazole for Schizophrenia
por: Priya, Lakshmi, et al.
Publicado: (2021)

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
por: Lauriello, John, et al.
Publicado: (2021)

Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores
por: Ismail, Zahinoor, et al.
Publicado: (2017)

Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate
por: Potkin, Steven G., et al.
Publicado: (2016)

Aripiprazole-induced transient myopia: A rare entity
por: Praveen Kumar, K V, et al.
Publicado: (2018)

Matrix metalloproteinase-9 predicts pulmonary status declines in α(1)-antitrypsin deficiency
por: Omachi, Theodore A, et al.
Publicado: (2011)

Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness
por: Velligan, Dawn I, et al.
Publicado: (2017)

Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study
por: Potkin, Steven G., et al.
Publicado: (2017)

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder
por: Citrome, Leslie
Publicado: (2006)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Effect of Aripiprazole on Cognitive Function and Hyperprolactinemia in Patients with Schizophrenia Treated with Risperidone
por: Lee, Bong Ju, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7v1s0qg22pns5g91f95aja6bhq